Posted on 10/12/2009 in Pharmaceutical Company Product News GlaxoSmithKline revealed this week that it has initiated a second phase III trial into the investigational Lp-PLA2 inhibitor darapladib and its effectiveness in treating adults suffering from acute coronary syndrome.
Overall, 11,500 patients from over 40 countries will participate in the study, which will evaluate the clinical efficacy of the long-term use of darapladib compared to placebo when both are added to standard of care.
It will test whether darapladib affects the risk of having a cardiovascular event, such as a heart attack or stroke.
Patrick Vallance, senior vice-president of drug discovery at GlaxoSmithKline, commented: "With more than 27,000 patients, the combined phase III clinical programme for darapladib will be one of the largest ever conducted to evaluate the efficacy and safety of any cardiovascular medication."
In other GlaxoSmithKline news, the firm announced this week that its Nicorette brand has launched a new TV, magazine and newspaper advertisement drive. Other news stories from 10/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
